97421-13-1

Basic information

• Product Name: 1-tert-butyl-1H-pyrazol-4-amine
• Synonyms: 1H-Pyrazol-4-aMine, 1-(1,1-diMethylethyl)-;1-tert-butyl-1H-pyrazol-4-amine;1-tert-butylpyrazol-4-amine
• CAS NO: 97421-13-1
• Molecular Formula: C₇H₁₃N₃
• Molecular Weight: 139.19822
• Mol File: 97421-13-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 1-tert-butyl-1H-pyrazol-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-tert-butyl-1H-pyrazol-4-amine(97421-13-1)
• EPA Substance Registry System: 1-tert-butyl-1H-pyrazol-4-amine(97421-13-1)

Safety Data

• Hazardous Substances Data: 97421-13-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
1-tert-butyl-1H-pyrazol-4-amine is utilized as a building block in the synthesis of a variety of pharmaceutical and agrochemical compounds. Its unique structure and functional groups contribute to the development of new molecules with therapeutic or pesticidal properties.
Used in Organic Synthesis:
As a versatile compound, 1-tert-butyl-1H-pyrazol-4-amine is employed in organic synthesis for the creation of complex organic molecules. Its compatibility with a wide range of reagents and solvents facilitates its use in multiple synthetic pathways.
Used in Research and Development:
1-tert-butyl-1H-pyrazol-4-amine is used as a subject of research for exploring its potential biological activities. Its anti-inflammatory and anti-cancer properties are of particular interest, as they could lead to the discovery of new therapeutic agents.
Used in Drug Development:
Due to its potential biological activities, 1-tert-butyl-1H-pyrazol-4-amine is employed in drug development programs. It may serve as a precursor or a key intermediate in the synthesis of new drugs targeting inflammation and cancer.

Upstream product

• 97421-12-0 1-tert-butyl-4-nitropyrazole 

Downstream Products

• 857266-91-2 phenyl 1-tert-butyl-1H-pyrazol-4-ylcarbamate 
• 1188910-65-7 1-(1-tert-butyl-1H-pyrazol-4-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)urea 

Relevant articles and documents

ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to a compound suitable for use as a kinase inhibitor

Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors

BTK is a promising target for the treatment of multiple diseases such as B cell malignances, asthma, and rheumatoid arthritis. Here, we report the discovery of a series of novel pyrimidine analogs as potent, highly selective, non-covalent inhibitors of BTK. Compound 25d demonstrated higher affinity to an unactivated conformation of BTK that resulted in an excellent kinase selectivity. Compound 25d showed a good oral bioavailability in mice, and significantly inhibits the PCA reaction in mice.

FGFR2 MODULATORS

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein:R3a, R2, R3b, R4b, L1, G and J are as defined in the specification, pharmaceutical compositionsthereof, and methods of use thereof.

N-Phenyl-N′-[4-(5H-pyrrolo[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as novel inhibitors of VEGFR and FGFR kinases

We have recently reported the discovery of pyrrolo[3,2-d]pyrimidine derivatives 1a and 1b as potent triple inhibitors of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and Tie-2 kinases. To identify compounds having strong inhibitory activity against fibroblast growth factor receptor (FGFR) kinase, further modification was conducted using the co-crystal structure analysis of VEGFR2 and 1b. Among the compounds synthesized, urea derivative 11l having a piperazine moiety on the terminal benzene ring showed strong inhibitory activity against FGFR1 kinase as well as VEGFR2 kinase. A binding model of 11l complexed with VEGFR2 suggested that the piperazine moiety forms additional interactions with Ile1025 and His1026.